Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …

Several hemolytic markers are available to guide the differential diagnosis and to monitor
treatment of hemolytic conditions. They include increased reticulocytes, an indicator of …

Guidelines Committee and the sounding board of BSH. It was also placed on the members
section of the BSH website for comment. It has also been reviewed by Royal College of …

The most frequent and feared complication of paroxysmal nocturnal hemoglobinuria (PNH)
is thrombosis. Recent research has demonstrated that the complement and coagulation …

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the
introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for …

Eculizumab is the first and only medication approved for paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment …

Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by chronic, uncontrolled
complement activation resulting in elevated intravascular haemolysis and morbidities …

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder
with increased mortality and morbidity resulting from intravascular hemolysis. Eculizumab, a …

Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic
anemia, bone marrow failure, thrombosis, and, frequently, poor quality of life. The …

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell
disorder characterized by a somatic mutation in the PIGA gene, leading to a deficiency of …